Navigation Links
Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
Date:10/30/2007

EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), a specialty biopharmaceutical company, today announced the pricing of an underwritten offering of its common stock to raise $60 million in gross proceeds at a public offering price of $2.75 per share. All of the shares in the offering are being sold by the Company. The offering is expected to close on November 2, 2007 and the Company will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs.

Merriman Curhan Ford & Co. (Amex: MEM) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager.

Copies of the final prospectus may be obtained from:

Merriman Curhan Ford & Co.

600 California Street, 9th Floor

San Francisco, CA 94108

via phone: (415) 248-5600

via fax: (415) 248-5690

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous syst
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015   BioClinica ® , Inc., a ... that David Peters , an accomplished senior finance ... and Chief Financial Officer (CFO) and will be joining ... more than 25 years of financial and accounting experience ... and deep knowledge in all areas of finance, accounting ...
(Date:6/2/2015)... 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, ... announced that the Special Committee of the Company,s board of ... ( China ) Limited as its independent financial ... its United States legal counsel and ...
(Date:6/2/2015)... 2015 MGB Biopharma at ... problem  MGB Biopharma, a biopharmaceutical company ... address the major global problem of antibiotic resistance ... intravenous (IV) formulation of MGB-BP-3, designed for the treatment ... The intravenous formulation of MGB-BP-3 is currently ...
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals ... Eliseo Oreste Salinas , MD, MSc,  has joined ... Dr. Salinas, who holds a medical ... brings a record of significant accomplishments in the ... Dr. Salinas has played a leadership ...
Breaking Biology Technology:BioClinica Names David Peters New Chief Financial Officer 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... ... , ... , , ... ...
... ... ... , ... , , , ...
... ... ... , ... ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2009 2Amsterdam Molecular Therapeutics Reports Full Year Results 2009 3Amsterdam Molecular Therapeutics Reports Full Year Results 2009 4Amsterdam Molecular Therapeutics Reports Full Year Results 2009 5Amsterdam Molecular Therapeutics Reports Full Year Results 2009 6Amsterdam Molecular Therapeutics Reports Full Year Results 2009 7Amsterdam Molecular Therapeutics Reports Full Year Results 2009 8Amsterdam Molecular Therapeutics Reports Full Year Results 2009 9Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 2Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 3Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 4Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 5Predicted Second Wave of Biotech Growth and Development Begins 2Predicted Second Wave of Biotech Growth and Development Begins 3Predicted Second Wave of Biotech Growth and Development Begins 4Predicted Second Wave of Biotech Growth and Development Begins 5Predicted Second Wave of Biotech Growth and Development Begins 6Predicted Second Wave of Biotech Growth and Development Begins 7Predicted Second Wave of Biotech Growth and Development Begins 8Predicted Second Wave of Biotech Growth and Development Begins 9Predicted Second Wave of Biotech Growth and Development Begins 10Predicted Second Wave of Biotech Growth and Development Begins 11
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Brain cells in a mouse model of Alzheimer's,disease ... the disorder's characteristic brain plaques are removed.,Researchers at ... mice with an antibody for a key component ... areas of the brain where,antibodies cleared plaques, many ...
... with aiding efforts to study addicted,smokers, a new ... brain that have,been implicated in nicotine addiction ... such as Alzheimer’s,disease and schizophrenia.,Developed by UC Irvine ... ?Nifrolidine ?is a selective binding agent,that identifies specific ...
... cells have been contaminated with a non-human molecule ... to research by investigators at the University of ... Salk Institute in La Jolla,California.,In a study published ... the researchers found that human embryonic stem cells,including ...
Cached Biology News:Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 2Mouse brain cells rapidly recover after Alzheimer's plaques are cleared 3Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 2Current human embryonic stem cell lines contaminated UCSD/Salk team finds 3Current human embryonic stem cell lines contaminated UCSD/Salk team finds 4
... Molecular Probes intensely fluorescent and highly ... for use in a variety of ... a strong signal. Unfortunately, protein- and ... that may cause them to bind ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
...
Biology Products: